Find Research Projects

Search results

• A phase 1/2 open label, multi-center dose escalation and expansion study of combination immunotherapy CBT-501 (anti-PD-1) or nivolumab with CBT-101 (c-Met inhibitor) in locally advanced or metastatic hepatocellular carcinoma and renal cell carcinoma

  Sabanathan, D., Chapman, N., Butala, R. & Gurney, H.

  16/05/19 → 15/05/24

  Project: Other

• A phase 1/2 open label, multi-center dose escalation and expansion study of combination immunotherapy CBT-501 (anti-PD-1) or nivolumab with CBT-101 (c-Met inhibitor) in locally advanced or metastatic hepatocellular carcinoma and renal cell carcinoma

  Sabanathan, D., Chapman, N., Butala, R. & Gurney, H.

  16/05/19 → 15/05/24

  Project: Other

• A Phase 1B, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Ipatasertib in Combination with Rucaparib in patients with Advanced Breast, Ovarian, or Prostate Cancer

  Gurney, H., Chapman, N. & Butala, R.

  5/08/19 → 26/06/24

  Project: Other

• A Phase 1B/2 study to evaluate safety and anti-tumour activity of AVELUMAB in combination with POLY (ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) inhibitor TALAZOPARIB in patients with locally advance or metastatic solid tumours

  Sabanathan, D., Kefford, R., Butala, R. & Cunningham, J.

  19/07/18 → 5/01/21

  Project: Research

• XL184-021: A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

  Park, J., Sabanathan, D., Gurney, H., Chapman, N. & Rai, M.

  28/08/20 → 30/04/25

  Project: Research

• MT-5111_001: A Phase 1b Open-label, Multicenter Dose Escalation and Expansion Study of MT-5111 in Subjects With Previously Treated Advanced HER2-positive Solid Tumors

  Sabanathan, D., Park, J. & Chapman, N.

  13/12/21 → 12/12/26

  Project: Research

• C0541001: A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF 06804103 IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) POSITIVE AND NEGATIVEe SOLID TUMORS

  Sabanathan, D. & Chapman, N.

  21/09/20 → 31/05/25

  Project: Research

• SHR-A1811-1-101: A Phase 1 Multi-Country, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A1811 in HER2 Expressing or Mutated Advanced Malignant Solid Tumor Subjects

  Park, J. & Chapman, N.

  28/09/20 → 31/12/22

  Project: Research

• ZN-c5-002: A Phase 1 Open-Label, Multicenter Study to Evaluate Biomarkers for ZN-c5 in Subjects with EstrogenReceptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.

  Sabanathan, D., Park, J. & Chapman, N.

  15/10/20 → 23/07/21

  Project: Research

• Harbour Biomed 4003.1: A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of HBM4003 in Subjects with Advanced Solid Tumors

  Gurney, H., Chapman, N., Butala, R., Parshionikar, A. & Rajasekharan Nair, A.

  30/09/19 → 30/09/24

  Project: Other

• HP518-CS-001: A Phase 1 open-label study to assess the safety, pharmacokinetics and anti-tumor activity of oral HP518 in patients with metastatic castration-resistant prostate cancer

  Gurney, H. & Chapman, N.

  17/01/22 → 13/12/26

  Project: Research

• MISC_Covance Chiltern: A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting Programmed Death Ligand 1 (PD-L1) Protein in Patients with Advanced Solid Tumors

  Gurney, H., Butala, R. & Cunningham, J.

  16/07/18 → 15/07/23

  Project: Other

• MEND: A Phase 1 Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy Study of Oral Monepantel in patients with ALS/Motor Neuron Disease

  Rowe, D., Gan, R., Bayeh, P. & Kalband, B.

  1/07/22 → 30/06/27

  Project: Research

• CYCLONE 2: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer

  Gurney, H., Chapman, N., Cunningham, J. & Butala, R.

  1/12/18 → 30/11/23

  Project: Other

• GALAXI: A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease

  Leong, R., Butala, R., Chapman, N., Parshionikar, A. & Rajasekharan Nair, A.

  30/09/19 → 7/05/24

  Project: Research

• APOLLO-CD: A Phase 2a, Multi-Center, Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of PRA023 in Subjects with Moderately to Severely Active Crohn’s Disease

  Leong, R. & Chapman, N.

  8/02/22 → 28/07/26

  Project: Research

• REAL: A Phase 2a Open-Label Preliminary Safety, Efficacy, and Biomarker Study of WP-0512 in Patients with Amyotrophic Lateral Sclerosis (ALS) REAL (Rho kinasE in ALs)

  Rowe, D., Gan, R. & Bayeh, P.

  13/05/22 → 31/05/27

  Project: Research

• VEGA: A Phase 2a Randomized, Double-blind, Active-controlled, Parallel-group, Multicenter, Proof-of-concept Clinical Study to Evaluate the Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

  Leong, R., Butala, R. & Chapman, N.

  24/09/19 → 11/07/24

  Project: Other

• A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies

  Gurney, H., Cunningham, J. & Butala, R.

  17/10/18 → 4/09/23

  Project: Other

• ACT16849: A Phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants with lung cancer or pleural mesothelioma

  Park, J., Chapman, N. & Tan, P.

  13/05/21 → 15/04/26

  Project: Research

• A Phase 2 Open Label Trial of 3K3A-APC in Amyotrophic Lateral Sclerosis.

  Rowe, D., Gan, R. & Bayeh, P.

  Project: Research

  File

• GS-US-548-5916: A Phase 2 Study of Magrolimab Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma

  Park, J., Sabanathan, D., Xia, C. Y., Kim, S. & Chapman, N.

  3/08/21 → 29/07/26

  Project: Research

• A Phase 3, multicenter, randomized, open-label, active-controlled study of DS-8201a, an anti-HER2-antibody drug conjugate, versus treatment of investigator’s choice for HER2-positive, unresectable and/or metastatic breast cancer subjects pretreated with prior standard of care HER2 therapies, including T-DM1

  Kefford, R., Butala, R. & Cunningham, J.

  12/03/19 → 25/11/23

  Project: Other

• A phase 3, placebo controlled, doubleblind,randomized, clinical study to determine efficacy, safety and tolerability of pulsed,inhaled nitric oxid (iNO) versus placebo in symptomatic subjects with

  Brown, M. & Butala, R.

  11/11/16 → 30/09/18

  Project: Research

• ADVANCE capacity: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by Cardiopulmonary Exercise Testing in Subjects with World Health Organization Group 1 Pulmonary Hypertension Who Recently Initiated Therapy

  Brown, M., Chapman, N., Rai, M. & Parshionikar, A.

  1/07/20 → 31/03/25

  Project: Research

• ADVANCE-outcomes: A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH: APD811-301

  Brown, M., Butala, R. & Chapman, N.

  17/10/19 → 30/06/22

  Project: Research

• LEAP-011: A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression: Protocol MK7902-011-00

  Zhang, A., Butala, R. & Chapman, N.

  13/09/19 → 6/06/24

  Project: Research

• A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer.

  Zhang, A., Chapman, N. & Butala, R.

  6/08/19 → 18/06/24

  Project: Other

• KEYLYNK-010: A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration resistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy

  Gurney, H., Butala, R. & Chapman, N.

  9/09/19 → 26/11/20

  Project: Other

• M14-533: A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis

  Leong, R., Chapman, N., Parshionikar, A. & Rajasekharan Nair, A.

  17/12/19 → 26/09/24

  Project: Research

• ADVANCE-outcomes 303: A phase 3 open-label extension (OLE) study to evaluate the long-term safety and efficacy of ralinepag in subjects with World Health Organisation (WHO) Group 1 pulmonary arterial hypertension (PAH): ADP811-303

  Brown, M., Butala, R. & Chapman, N.

  17/10/19 → 30/06/22

  Project: Research

• Checkmate 914: A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse

  Gurney, H., Chapman, N. & Zhang, A.

  17/08/20 → 4/06/25

  Project: Research

• CONTACT-02: A phase 3 randomized, open label, controlled study of cabozantinib (XL184) in combination with Atezolizumab vs second novel hormonal therapy in subjects with high-risk, metastatic castration-resistant prostate cancer

  Gurney, H., Zhang, A. & Chapman, N.

  3/09/21 → 29/04/26

  Project: Research

• AMPLITUDE: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

  Gurney, H. & Chapman, N.

  30/11/20 → 15/10/25

  Project: Research

• A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer

  Gurney, H. & Cunningham, J.

  4/04/19 → 3/04/24

  Project: Other

• A Phase 3 Randomized, Placebo-Controlled Trial With a Longitudinal Natural History Run-In and Open-Label Extension to Evaluate BIIB067 Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation

  Rowe, D., Gan, R. & Bayeh, P.

  Project: Research

  File

• A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined with Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients with Previously Untreated Advanced Renal Cell Carcinoma

  Gurney, H., Chapman, N. & Butala, R.

  28/02/19 → 27/02/24

  Project: Other

• KEYNOTE-905: A Phase 3 Randomized Study of Cystectomy plus Perioperative Pembrolizumab versus Cystectomy Alone in Cisplatin-ineligible Participants with Muscle-invasive Bladder Cancer (MK3475-905)

  Zhang, A., Chapman, N. & Parshionikar, A.

  13/09/19 → 10/08/20

  Project: Other

• Bayer 20510: A Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of radium-223 dichloride vs. standard doses of novel anti-hormonal therapy (NAH) in patients with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of NAH

  Gurney, H. & Chapman, N.

  1/12/20 → 10/09/25

  Project: Research

• CN1-101: A phase I, open label, multi-center,dose escalation clinical study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CN1 in patients with advanced solid tumors or B-cell lymphoma

  Park, J., Chapman, N., Gurney, H. & Sabanathan, D.

  3/08/20 → 30/06/25

  Project: Research

• CS1001/Regorafenib-101: A phase Ib/II multicenter open-label study of CS1001 in combination with regorafenib in patients with advanced or refractory solid tumors

  Park, J., Gurney, H., Parshionikar, A., Chapman, N. & Rai, M.

  Project: Research

• iPredict: A Phase IIB, Open Label, Study of 89Zr-Df-Crefmirlimab PET/CT in Subjects with Selected Advanced or Metastatic Malignancies including Melanoma, Merkel Cell, Renal Cell and Non-Small Cell Lung Cancers, 2 scheduled to Receive Standard-of-Care Immunotherapy (IOT) as a Single Agent or Combination, to Predict Response to Therapy

  Zhang, A., Chester, C. & Chapman, N.

  21/01/22 → 9/12/26

  Project: Research

• IPATunity170: A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Of Ipatasertib In Combination With Atezolizumab And Paclitaxel As A Treatment For Patients With Locally Advanced Unresectable Or Metastatic Triple-Negative Breast Cancer

  Kefford, R., Chapman, N., Parshionikar, A. & Rajasekharan Nair, A.

  22/11/19 → 30/09/24

  Project: Other

• IPATunity170: A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Of Ipatasertib In Combination With Atezolizumab And Paclitaxel As A Treatment For Patients With Locally Advanced Unresectable Or Metastatic Triple-Negative Breast Cancer

  Kefford, R., Chapman, N., Parshionikar, A. & Rajasekharan Nair, A.

  22/11/19 → 30/09/24

  Project: Other

• IPATunity170: A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Of Ipatasertib In Combination With Atezolizumab And Paclitaxel As A Treatment For Patients With Locally Advanced Unresectable Or Metastatic Triple-Negative Breast Cancer

  Kefford, R., Chapman, N., Parshionikar, A. & Rajasekharan Nair, A.

  22/11/19 → 30/09/24

  Project: Other

• IPATunity170: A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Of Ipatasertib In Combination With Atezolizumab And Paclitaxel As A Treatment For Patients With Locally Advanced Unresectable Or Metastatic Triple-Negative Breast Cancer

  Kefford, R., Chapman, N., Parshionikar, A. & Rajasekharan Nair, A.

  22/11/19 → 30/09/24

  Project: Other

• A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects with Pulmonary Arterial HTN Receiving Background Oral Monotherapy

  Brown, M. & Butala, R.

  1/11/15 → 30/11/18

  Project: Research

• A Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti-PD-L1 Antibody) in combination with adjuvant Anthracycline/Taxane-based Chemotherapy versus Chemotherapy Alone in patients with operable Triple-Negative Breast Cancer

  Sabanathan, D., Kefford, R., Chapman, N. & Butala, R.

  5/08/19 → 24/10/23

  Project: Other

• WO41994: A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB GIVEN IN COMBINATION WITH CABOZANTINIB VERSUS CABOZANTINIB ALONE IN PATIENTS WITH INOPERABLE, LOCALLY ADVANCED, OR METASTATIC RENAL CELL CARCINOMA WHO EXPERIENCED RADIOGRAPHIC TUMOR PROGRESSION DURING OR AFTER IMMUNE CHECKPOINT INHIBITOR TREATMENT

  Gurney, H., Zhang, A. & Chapman, N.

  1/08/20 → 25/06/25

  Project: Research

• A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant TriAl with Ribociclib [LEE011]: NATALEE)

  Sabanathan, D., Kefford, R. & Cunningham, J.

  21/03/19 → 20/03/24

  Project: Other